% Generated by roxygen2: do not edit by hand
% Please edit documentation in R/stagemigration.h.R
\name{stagemigration}
\alias{stagemigration}
\title{Advanced TNM Stage Migration Analysis}
\usage{
stagemigration(
  data,
  oldStage = NULL,
  newStage = NULL,
  survivalTime = NULL,
  event = NULL,
  eventLevel,
  clinicalPreset = "routine_clinical",
  enableGuidedMode = TRUE,
  generateCopyReadyReport = TRUE,
  enableAccessibilityFeatures = FALSE,
  preferredLanguage = "en",
  enableProgressIndicators = TRUE,
  optimizeForLargeDatasets = FALSE,
  analysisType = "comprehensive",
  confidenceLevel = 0.95,
  calculateNRI = FALSE,
  nriTimePoints = "12, 24, 60",
  calculateIDI = FALSE,
  performROCAnalysis = FALSE,
  rocTimePoints = "12, 24, 36, 60",
  performDCA = FALSE,
  performCalibration = FALSE,
  performBootstrap = FALSE,
  bootstrapReps = 1000,
  performCrossValidation = FALSE,
  cvFolds = 5,
  institutionVariable = NULL,
  clinicalSignificanceThreshold = 0.02,
  nriClinicalThreshold = 0.2,
  performHomogeneityTests = FALSE,
  performTrendTests = FALSE,
  performLikelihoodTests = FALSE,
  calculatePseudoR2 = TRUE,
  showMigrationOverview = TRUE,
  showMigrationSummary = TRUE,
  showStageDistribution = TRUE,
  showMigrationMatrix = TRUE,
  showStatisticalComparison = TRUE,
  showConcordanceComparison = TRUE,
  showMigrationHeatmap = FALSE,
  showSankeyDiagram = FALSE,
  showROCComparison = FALSE,
  showCalibrationPlots = FALSE,
  showDecisionCurves = FALSE,
  showForestPlot = FALSE,
  showWillRogersAnalysis = FALSE,
  showWillRogersVisualization = FALSE,
  showMigrationSurvivalComparison = FALSE,
  showSurvivalCurves = FALSE,
  survivalPlotType = "separate",
  showConfidenceIntervals = FALSE,
  showRiskTables = FALSE,
  plotTimeRange = "auto",
  showClinicalInterpretation = FALSE,
  showStatisticalSummary = FALSE,
  showMethodologyNotes = FALSE,
  includeEffectSizes = FALSE,
  advancedMigrationAnalysis = FALSE,
  generateExecutiveSummary = FALSE,
  cancerType = "general",
  useOptimismCorrection = FALSE,
  enableMultifactorialAnalysis = FALSE,
  continuousCovariates = NULL,
  categoricalCovariates = NULL,
  multifactorialComparisonType = "comprehensive",
  baselineModel = "covariates_only",
  performInteractionTests = FALSE,
  stratifiedAnalysis = FALSE,
  showMultifactorialTables = FALSE,
  showAdjustedCIndexComparison = FALSE,
  showNestedModelTests = FALSE,
  showStepwiseResults = FALSE,
  showExplanations = TRUE,
  showAbbreviationGlossary = FALSE,
  calculateSME = FALSE,
  calculateRMST = FALSE,
  performCompetingRisks = FALSE,
  competingEventVar = NULL,
  performOptimalCutpoint = FALSE,
  continuousStageVariable = NULL,
  cutpointMethod = "maxstat",
  cutpointRange = "0.1, 0.9",
  multipleTestingCorrection = "bonferroni",
  validateCutpoint = FALSE,
  cutpointBootstrap = FALSE,
  cutpointBootstrapReps = 500,
  generateStagingSystem = FALSE,
  stagingSystemLevels = 3,
  performSHAPAnalysis = FALSE,
  shapAnalysisType = "comprehensive",
  shapCovariates = NULL,
  shapSampleSize = 100,
  shapBackgroundSamples = 50,
  shapExplanationType = "auto",
  generateSHAPPlots = TRUE,
  shapPatientProfiles = "representative",
  shapInteractionAnalysis = FALSE,
  shapClinicalThresholds = "0.25, 0.50, 0.75",
  performCompetingRisksAdvanced = FALSE,
  competingRisksMethod = "comprehensive",
  cifTimePoints = "12, 24, 36, 60",
  competingEventLevels = "cancer_death, other_death, censored",
  primaryEventLevel = "cancer_death",
  generateCIFPlots = TRUE,
  performGrayTest = TRUE,
  cifConfidenceLevel = 0.95,
  competingRisksCovariates = NULL,
  stratifyByStaging = TRUE,
  calculateCRCIndex = TRUE,
  generateCRSummary = TRUE,
  performMultiStateAnalysis = FALSE,
  multiStateModel = "illness_death",
  stateVariable = NULL,
  transitionTimeVariable = NULL,
  multiStateStates = "healthy, disease, death",
  absorptionStates = "death",
  multiStateCovariates = NULL,
  calculateTransitionProbabilities = TRUE,
  multiStateTimePoints = "6, 12, 24, 36, 60",
  generateTransitionMatrix = TRUE,
  multiStateGraphics = TRUE,
  msStratifyByStaging = TRUE,
  multiStateValidation = FALSE,
  generateMSMSummary = TRUE,
  performRandomForestAnalysis = FALSE,
  forestModelType = "rsf",
  forestNTrees = 500,
  forestMTry = "auto",
  forestMinNodeSize = 3,
  forestCovariates = NULL,
  calculateVariableImportance = TRUE,
  forestImportanceType = "permutation",
  performForestValidation = FALSE,
  forestPredictionTimePoints = "12, 24, 36, 60",
  generateSurvivalPredictions = TRUE,
  forestDiscriminationMetrics = TRUE,
  forestStagingComparison = TRUE,
  forestBootstrap = FALSE,
  forestBootstrapSamples = 100,
  generateForestSummary = TRUE,
  performCureModelAnalysis = FALSE,
  cureModelType = "mixture",
  cureDistribution = "weibull",
  cureAnalyzeOldStage = TRUE,
  cureAnalyzeNewStage = TRUE,
  cureFractionEstimation = "parametric",
  cureConfidenceLevel = 0.95,
  cureBootstrapCI = TRUE,
  cureBootstrapReps = 500,
  cureTimeHorizon = 120,
  curePlateauThreshold = 0.05,
  cureCovariates = NULL,
  cureModelComparison = TRUE,
  cureStageSpecificAnalysis = TRUE,
  cureGoodnessOfFit = TRUE,
  generateCureSummary = TRUE,
  performIntervalCensoringAnalysis = FALSE,
  intervalCensoringLeftTime = NULL,
  intervalCensoringRightTime = NULL,
  intervalCensoringDistribution = "weibull",
  intervalCensoringModel = "both",
  intervalCensoringBootstrap = TRUE,
  intervalCensoringBootstrapSamples = 1000,
  intervalCensoringCompareStages = TRUE,
  intervalCensoringPlots = TRUE,
  intervalCensoringDiagnostics = TRUE,
  intervalCensoringPredictionTime = "12, 24, 36, 60",
  intervalCensoringConfidenceLevel = 0.95,
  intervalCensoringAdjustVariables = NULL,
  performInformativeCensoringAnalysis = FALSE,
  informativeCensoringTestMethod = "all_tests",
  informativeCensoringCovariates = NULL,
  informativeCensoringLandmarkTimes = "12, 24, 36, 60",
  informativeCensoringAdjustmentMethod = "sensitivity_analysis",
  informativeCensoringIPWVariables = NULL,
  informativeCensoringSensitivityRange = "0.8, 0.9, 1.0, 1.1, 1.2",
  informativeCensoringBootstrap = TRUE,
  informativeCensoringBootstrapSamples = 1000,
  informativeCensoringAlpha = 0.05,
  informativeCensoringPlots = TRUE,
  informativeCensoringCompareStages = TRUE,
  performConcordanceProbabilityAnalysis = FALSE,
  concordanceProbabilityMethods = "all_methods",
  concordanceProbabilityTimePoints = "12, 24, 36, 60, 120",
  concordanceProbabilityWeighting = "uniform",
  concordanceProbabilityBootstrap = TRUE,
  concordanceProbabilityBootstrapSamples = 1000,
  concordanceProbabilityConfidenceLevel = 0.95,
  concordanceProbabilityCompareStages = TRUE,
  concordanceProbabilityAdjustVariables = NULL,
  concordanceProbabilityRobustnessAnalysis = TRUE,
  concordanceProbabilityAlpha = 0.05,
  concordanceProbabilityDiagnostics = TRUE,
  performWinRatioAnalysis = FALSE,
  winRatioEndpoints = "death_progression_response",
  winRatioDeathVariable = NULL,
  winRatioSecondaryEndpoint = NULL,
  winRatioTertiaryEndpoint = NULL,
  winRatioTimeVariables = NULL,
  winRatioMatchingStrategy = "all_pairs",
  winRatioConfidenceMethod = "bootstrap",
  winRatioBootstrapSamples = 1000,
  winRatioConfidenceLevel = 0.95,
  winRatioHandleTies = "next_endpoint",
  winRatioSensitivityAnalysis = TRUE,
  winRatioGeneralizedPairwise = FALSE,
  performFrailtyModelsAnalysis = FALSE,
  frailtyClusterVariable = NULL,
  frailtyDistribution = "gamma",
  frailtyBootstrap = TRUE,
  frailtyBootstrapSamples = 500,
  frailtyVarianceComponents = TRUE,
  frailtyHeterogeneityTest = TRUE,
  frailtyClusterComparison = FALSE,
  frailtyModelSelection = TRUE,
  frailtyPredictiveAccuracy = FALSE,
  frailtyDiagnostics = TRUE,
  frailtyAdvancedInference = FALSE,
  performClinicalUtilityAnalysis = FALSE,
  clinicalUtilityPrevalence = 0.2,
  clinicalUtilityTimePoint = 60,
  clinicalUtilityThresholds = "standard",
  clinicalUtilityNNT = TRUE,
  clinicalUtilityTreatmentEffect = 0.7,
  clinicalUtilityComparison = TRUE,
  clinicalUtilityCostEffectiveness = FALSE,
  clinicalUtilityCostPerIntervention = 5000,
  clinicalUtilityBootstrap = TRUE,
  clinicalUtilityBootstrapSamples = 500,
  clinicalUtilityTimeVarying = FALSE
)
}
\arguments{
\item{data}{The dataset containing staging and survival information for TNM
validation analysis.}

\item{oldStage}{ðŸ“‹ CLINICAL EXAMPLE: Select your current staging variable
such as 'TNM7_Stage'  containing values like: Stage I, Stage IIA, Stage
IIB, Stage IIIA, Stage IIIB, Stage IV. ðŸ” TECHNICAL DETAILS: The original
staging variable (e.g., TNM 7th edition, AJCC 7th edition). Should be coded
as ordered factor with appropriate stage levels for meaningful comparison.}

\item{newStage}{ðŸ“‹ CLINICAL EXAMPLE: Select your new staging variable such
as 'TNM8_Stage'  containing the same patients but potentially different
stage assignments based on  revised criteria (e.g., T descriptor changes,
nodal assessment updates). ðŸ” TECHNICAL DETAILS: The proposed new staging
variable (e.g., TNM 8th edition, revised staging). Should use the same
coding structure as the original staging system for valid comparison.}

\item{survivalTime}{ðŸ“‹ CLINICAL EXAMPLE: Select your follow-up time
variable such as 'OS_months'  containing values like: 12.5, 24.8, 36.2,
45.0 (months from diagnosis to death or last contact). ðŸ” TECHNICAL
DETAILS: Time to event or censoring in consistent units (months
recommended). For overall survival analysis, use time from diagnosis to
death or last follow-up. For disease-free survival, use time from treatment
to recurrence or last follow-up.}

\item{event}{ðŸ“‹ CLINICAL EXAMPLE: Select your event variable such as
'Death_Status'  containing values like: 0 (alive/censored), 1 (dead/event
occurred) OR  "Alive", "Dead" OR "No Event", "Death", "Disease
Progression". ðŸ” TECHNICAL DETAILS: Event indicator (1 = event occurred, 0
= censored) or factor with event levels. For overall survival, event =
death from any cause. For disease-specific survival,  event = death from
the specific disease being studied.}

\item{eventLevel}{The level indicating event occurrence when using factor
variables.}

\item{clinicalPreset}{Choose a preset tailored to your clinical workflow.
'Routine Clinical' provides essential  validation metrics for daily
practice. 'Research Study' adds advanced statistics for  academic research.
'Publication Ready' includes all methods and visualizations for
manuscripts. Choose 'Custom' to manually configure all options.}

\item{enableGuidedMode}{Enable step-by-step guidance for clinical users.
Provides contextual help,  assumption checking, and clinical interpretation
assistance throughout the analysis. Highly recommended for users new to
staging validation methods.}

\item{generateCopyReadyReport}{Generate plain-language clinical summary
paragraphs that can be copied directly  into reports or manuscripts.
Includes key findings, statistical significance,  clinical interpretation,
and implementation recommendations.}

\item{enableAccessibilityFeatures}{Enable accessibility features including
color-blind safe palettes,  high contrast visualizations, larger font
sizes, and enhanced table readability. Ensures outputs are accessible to
users with visual impairments.}

\item{preferredLanguage}{Choose the language for explanations, labels, and
clinical interpretations. Scientific terminology and statistical results
remain standardized.}

\item{enableProgressIndicators}{Show progress bars and status updates for
long-running analyses such as  bootstrap validation and cross-validation.
Helps users track analysis progress.}

\item{optimizeForLargeDatasets}{Enable memory-efficient processing for
large datasets (>10,000 patients).  Uses chunked processing and optimized
algorithms to reduce memory usage  and improve performance while
maintaining statistical accuracy.}

\item{analysisType}{Determines the scope of statistical analysis performed.
Comprehensive analysis includes all available methods for thorough staging
system validation.}

\item{confidenceLevel}{Confidence level for all confidence intervals and
hypothesis tests.}

\item{calculateNRI}{Calculate Net Reclassification Improvement to quantify
improvement in  risk classification between staging systems. Essential for
staging validation.}

\item{nriTimePoints}{Comma-separated time points for NRI calculation (e.g.,
"12, 24, 60" for  1, 2, and 5-year survival). Use clinically relevant time
points.}

\item{calculateIDI}{Calculate Integrated Discrimination Improvement to
measure improvement  in risk prediction accuracy between staging systems.}

\item{performROCAnalysis}{Perform time-dependent ROC analysis to compare
discriminative ability of staging systems over time.}

\item{rocTimePoints}{Time points for ROC analysis. Should include
clinically important survival milestones for the specific cancer type.}

\item{performDCA}{Perform Decision Curve Analysis to assess clinical
utility and net benefit of the new staging system for clinical decision
making.}

\item{performCalibration}{Assess calibration of risk predictions from both
staging systems. Important for validating accuracy of survival predictions.}

\item{performBootstrap}{Perform bootstrap validation with optimism
correction to assess internal validity of results. Recommended for all
staging validation studies.}

\item{bootstrapReps}{Number of bootstrap repetitions for internal
validation.  1000 repetitions recommended for stable results.}

\item{performCrossValidation}{Perform k-fold cross-validation for
additional validation. Computationally intensive but provides robust
validation.}

\item{cvFolds}{Number of folds for cross-validation when enabled.}

\item{institutionVariable}{Optional variable indicating institution or
study center for  multi-institutional validation. When provided, performs
internal-external cross-validation using k-1 centers for development and
remaining center for validation. Essential for multi-center staging
validation studies.}

\item{clinicalSignificanceThreshold}{Minimum improvement in C-index
considered clinically significant. Default 0.02 based on oncology
literature recommendations.}

\item{nriClinicalThreshold}{Minimum NRI improvement considered clinically
meaningful. Default 0.20 (20\\% net reclassification improvement).}

\item{performHomogeneityTests}{Test homogeneity within stages and monotonic
trend across stages. Essential for validating stage ordering and grouping.}

\item{performTrendTests}{Test for monotonic trend in survival across stage
levels. Validates that higher stages consistently have worse prognosis.}

\item{performLikelihoodTests}{Perform formal likelihood ratio tests
comparing nested staging models. Provides statistical significance testing
for staging improvement.}

\item{calculatePseudoR2}{Calculate multiple pseudo R-squared measures for
model comparison (Nagelkerke, McFadden, Cox-Snell).}

\item{showMigrationOverview}{Display overview table showing the fundamental
migration statistics including: total number of patients, number and
percentage of patients who migrated stages, direction of migration
(upstaged vs downstaged), and net migration effect. This is the essential
first table for understanding the overall impact of the new staging system.}

\item{showMigrationSummary}{Display statistical summary of migration
patterns including overall migration rate and formal statistical tests.
Shows Chi-square test results for independence and Fisher's exact test
p-values to determine if the migration patterns are statistically
significant. Essential for validating whether observed changes are due to
genuine staging improvements or random variation.}

\item{showStageDistribution}{Display side-by-side comparison of how
patients are distributed across stages in both the original and new staging
systems. Shows the count and percentage of patients in each stage, along
with the net change. This helps identify which stages are gaining or losing
patients and whether the new system creates better separation between
prognostic groups.}

\item{showMigrationMatrix}{Display detailed cross-tabulation matrix showing
exactly how patients moved between stages. Rows represent the original
staging system and columns represent the new staging system. Diagonal
values indicate patients who remained in the same stage, while off-diagonal
values show stage migrations. This is essential for understanding the
specific migration patterns and identifying which stages are most affected
by the new criteria.}

\item{showStatisticalComparison}{Display table with C-index comparisons and
other statistical metrics.}

\item{showConcordanceComparison}{Display detailed concordance comparison
between staging systems.}

\item{showMigrationHeatmap}{Display a color-coded heatmap visualization of
the migration matrix.  Darker colors indicate more patients, with the
diagonal showing patients  who remained in the same stage. This visual
representation makes it easy  to identify migration patterns at a glance -
upstaging appears above the  diagonal, downstaging below. Essential for
presentations and publications.}

\item{showSankeyDiagram}{Display a Sankey flow diagram showing patient
migration patterns between  original and new staging systems. Flow
thickness represents the number of  patients moving between stages, making
it easy to visualize dominant  migration patterns. Excellent for
presentations and understanding the  overall reclassification impact.}

\item{showROCComparison}{Display time-dependent ROC curves comparing
staging systems.}

\item{showCalibrationPlots}{Display calibration plots for both staging
systems.}

\item{showDecisionCurves}{Display decision curves showing net benefit of
staging systems.}

\item{showForestPlot}{Display forest plot with stage-specific hazard ratios
and confidence intervals.}

\item{showWillRogersAnalysis}{Detailed analysis of Will Rogers phenomenon
with survival comparisons between migrated and non-migrated patients within
stages.}

\item{showWillRogersVisualization}{Display visualization showing how stage
migration affects survival within each stage. Shows before/after survival
curves demonstrating the Will Rogers paradox where both stages appear to
improve.}

\item{showMigrationSurvivalComparison}{Display Kaplan-Meier survival curves
comparing the same stages before  and after patient migration. Shows how
survival curves change when  patients are reclassified between staging
systems, providing visual  evidence of the Will Rogers phenomenon and
staging system improvements.}

\item{showSurvivalCurves}{Display survival curves comparing the staging
systems.}

\item{survivalPlotType}{Controls display of survival curves for staging
system comparison.}

\item{showConfidenceIntervals}{Display confidence intervals around survival
curves and other estimates.}

\item{showRiskTables}{Display at-risk tables below survival curves.}

\item{plotTimeRange}{Maximum time for survival plots. Use "auto" for
automatic range or specify maximum months (e.g., "60" for 5-year
follow-up).}

\item{showClinicalInterpretation}{Display comprehensive clinical
interpretation of all statistical results with guidance for staging system
adoption decisions.}

\item{showStatisticalSummary}{Display comprehensive table summarizing all
statistical comparisons.}

\item{showMethodologyNotes}{Display detailed notes on statistical methods
used and their interpretation.}

\item{includeEffectSizes}{Calculate and display effect sizes for all
comparisons to assess practical significance beyond statistical
significance.}

\item{advancedMigrationAnalysis}{Perform comprehensive stage migration
analysis including monotonicity  checks, Will Rogers phenomenon detection,
stage-specific validation,  and enhanced discrimination metrics. Provides
detailed assessment of  staging system quality and migration patterns.}

\item{generateExecutiveSummary}{Generate executive summary with key
findings and recommendations for clinical and research stakeholders.}

\item{cancerType}{Optional cancer type specification for customized
thresholds and  interpretation guidelines based on cancer-specific
literature.}

\item{useOptimismCorrection}{Apply optimism correction to performance
metrics using bootstrap validation to avoid overly optimistic estimates.}

\item{enableMultifactorialAnalysis}{Enable advanced multifactorial stage
migration analysis that includes additional covariates in the comparison.
This allows for adjusted comparisons between staging systems after
accounting for other prognostic factors.}

\item{continuousCovariates}{Continuous variables to include as covariates
in the multifactorial analysis (e.g., age, tumor size, biomarker levels).
These will be included in Cox regression models for both staging systems.}

\item{categoricalCovariates}{Categorical variables to include as covariates
in the multifactorial analysis (e.g., sex, histology, treatment type).
These will be included in Cox regression models for both staging systems.}

\item{multifactorialComparisonType}{Type of multifactorial comparison to
perform. Comprehensive includes all methods for thorough evaluation of
staging systems in the context of other prognostic factors.}

\item{baselineModel}{Baseline model for multifactorial comparisons. This
determines the reference model against which staging systems are compared.}

\item{performInteractionTests}{Test for interactions between staging
systems and covariates. This helps identify if the staging system
performance varies across different patient subgroups.}

\item{stratifiedAnalysis}{Perform stratified analysis by categorical
covariates to evaluate staging system performance within subgroups.}

\item{showMultifactorialTables}{Display detailed tables showing
multifactorial model results, including adjusted hazard ratios and model
comparison statistics.}

\item{showAdjustedCIndexComparison}{Display comparison of C-indices for
staging systems adjusted for covariates. This shows the discriminative
ability of each staging system after accounting for other prognostic
factors.}

\item{showNestedModelTests}{Display likelihood ratio tests comparing nested
models to formally test the added value of each staging system over the
baseline model.}

\item{showStepwiseResults}{Display results of stepwise model selection
showing which variables (including staging systems) are selected in the
final model.}

\item{showExplanations}{Include detailed explanations for results.}

\item{showAbbreviationGlossary}{Display a comprehensive glossary of all
abbreviations, statistical terms,  and technical terminology used in the
stage migration analysis. This  provides a quick reference for interpreting
dashboard values and  understanding statistical outputs.}

\item{calculateSME}{Calculate Stage Migration Effect Formula (SME) to
quantify the cumulative  difference in survival between corresponding
stages of old and new staging  systems. SME = Î£(S_new_i - S_old_i) where S
represents stage-specific  survival rates. Positive values indicate Will
Rogers phenomenon (apparent  improvement in new system), while negative
values suggest understaging.}

\item{calculateRMST}{Calculate Restricted Mean Survival Time (RMST) metrics
for robust  discrimination assessment. RMST provides clinically
interpretable  survival measures that are independent of proportional
hazards assumptions.  Particularly valuable when median survival is not
reached or when comparing  absolute survival benefits between staging
systems.}

\item{performCompetingRisks}{Perform competing risks analysis for scenarios
with multiple event types  (e.g., cancer-specific death vs. other causes).
Implements Fine-Gray  subdistribution hazard models and Cumulative
Incidence Function (CIF)  analysis. Essential when competing events prevent
observation of primary  outcome and standard survival analysis may be
biased.}

\item{competingEventVar}{Optional variable indicating competing events
(events other than primary  outcome). If not specified, the analysis will
attempt to detect competing  risks from multi-level event variables. For
cancer studies, this typically  represents non-cancer deaths when primary
outcome is cancer-specific death.}

\item{performOptimalCutpoint}{Determine optimal cut-points for continuous
variables that create the most  statistically significant separation in
survival outcomes. Uses maximal  selected rank statistics with appropriate
multiple testing corrections.  Essential for developing new staging
criteria from continuous biomarkers  or measurements.}

\item{continuousStageVariable}{Continuous variable (e.g., tumor size,
biomarker level, age) for optimal  cut-point determination. The analysis
will find the cut-point that maximizes  the separation in survival outcomes
while controlling for multiple testing.}

\item{cutpointMethod}{Method for optimal cut-point determination. Maximal
selected rank statistics  provides the most rigorous approach with proper
multiple testing correction.}

\item{cutpointRange}{Proportion range for cut-point search (e.g., "0.1,
0.9" excludes outer  10\\% to maintain statistical power). Prevents extreme
cut-points that  create unbalanced groups.}

\item{multipleTestingCorrection}{Multiple testing correction method for
cut-point determination.  Bonferroni is most conservative; use when testing
many cut-points.}

\item{validateCutpoint}{Perform cross-validation to assess stability of
optimal cut-point.  Helps identify robust cut-points that are not dependent
on specific  data characteristics.}

\item{cutpointBootstrap}{Use bootstrap validation to assess cut-point
stability and derive  confidence intervals. Provides robust assessment of
cut-point reliability.}

\item{cutpointBootstrapReps}{Number of bootstrap repetitions for cut-point
validation.}

\item{generateStagingSystem}{Automatically generate a new staging system
based on optimal cut-points.  Creates categorical staging variable from
continuous measurements using  determined cut-points with appropriate stage
labeling.}

\item{stagingSystemLevels}{Number of staging levels to create from optimal
cut-points (e.g., 3 for  Low/Intermediate/High or 4 for Stages I-IV).}

\item{performSHAPAnalysis}{Perform Shapley Additive Explanations (SHAP)
analysis to explain which  factors are driving the predictions of staging
models. SHAP provides  both global feature importance and individual
patient-level explanations  for complex staging decisions.}

\item{shapAnalysisType}{Type of SHAP analysis to perform. Global analysis
shows overall feature  importance across all patients, individual analysis
explains specific  patient predictions, comprehensive includes both
approaches.}

\item{shapCovariates}{Additional variables to include in SHAP
interpretability analysis  alongside staging variables. Include key
clinical variables that  might influence staging decisions or patient
outcomes.}

\item{shapSampleSize}{Number of patients to use for SHAP analysis. Larger
samples provide  more comprehensive explanations but require more
computation time.  Recommended: 100-200 for routine analysis, 500+ for
detailed research.}

\item{shapBackgroundSamples}{Number of background samples for SHAP baseline
calculation. More  samples provide more stable explanations but increase
computation time.}

\item{shapExplanationType}{SHAP explanation method to use. Auto-detect
chooses the most appropriate  method based on the model type. TreeSHAP is
fastest for tree models,  Kernel SHAP works with any model but is slower.}

\item{generateSHAPPlots}{Generate SHAP visualization plots including
summary plots, bar plots,  and dependence plots for model interpretability.}

\item{shapPatientProfiles}{Types of patient profiles to include in
individual SHAP explanations.  Helps understand how different patient
characteristics influence  staging-based predictions.}

\item{shapInteractionAnalysis}{Perform SHAP interaction analysis to
identify important feature  interactions. Shows how combinations of
features affect predictions  beyond individual feature effects.}

\item{shapClinicalThresholds}{Comma-separated risk thresholds for clinical
decision boundaries in  SHAP analysis (e.g., "0.25, 0.50, 0.75" for
low/moderate/high risk).  Used to interpret SHAP values in clinical
context.}

\item{performCompetingRisksAdvanced}{Perform comprehensive competing risks
analysis using Fine-Gray  subdistribution hazard models and Cumulative
Incidence Function (CIF)  analysis. Essential when competing events prevent
observation of primary  outcome and standard survival analysis may be
biased.}

\item{competingRisksMethod}{Method for competing risks analysis. Fine-Gray
models cumulative  incidence, cause-specific models instantaneous hazard
rates.  Comprehensive includes both approaches for complete assessment.}

\item{cifTimePoints}{Time points for Cumulative Incidence Function analysis
(e.g.,  "12, 24, 36, 60" for 1, 2, 3, and 5-year analysis). Use clinically
relevant time points for the specific cancer type.}

\item{competingEventLevels}{Comma-separated list of event categories for
competing risks analysis.  Typically includes primary event (cancer death),
competing events  (other causes), and censoring indicator.}

\item{primaryEventLevel}{Specify the primary event of interest for
competing risks analysis  (e.g., "cancer_death", "disease_progression",
"cardiovascular_death").  Must match one of the competing event categories.}

\item{generateCIFPlots}{Generate Cumulative Incidence Function plots
showing probability of  each event type over time. Essential for
visualizing competing risks  patterns and staging system comparisons.}

\item{performGrayTest}{Perform Gray's test for equality of cumulative
incidence functions  across staging groups. Tests whether CIF curves differ
significantly  between stages for each event type.}

\item{cifConfidenceLevel}{Confidence level for Cumulative Incidence
Function confidence intervals  and statistical tests.}

\item{competingRisksCovariates}{Additional variables to include in
competing risks regression models.  Include important prognostic factors
that may influence both primary  and competing events.}

\item{stratifyByStaging}{Perform separate competing risks analysis for each
staging system  (original vs new) to compare their performance in the
presence of  competing events.}

\item{calculateCRCIndex}{Calculate C-index specifically adapted for
competing risks analysis.  Provides discrimination metrics that properly
account for competing  events when evaluating staging system performance.}

\item{generateCRSummary}{Generate comprehensive summary table with
Fine-Gray regression results,  cumulative incidence estimates, and staging
system comparisons in  competing risks context.}

\item{performMultiStateAnalysis}{Perform multi-state survival analysis for
complex disease progression  scenarios where patients can transition
between multiple health states  over time. Essential for modeling disease
progression, remission,  relapse, and death in oncology.}

\item{multiStateModel}{Type of multi-state model to fit. Illness-Death
models progression  from healthy to disease to death. Progression models
include stable,  progressive, terminal states. Comprehensive fits multiple
models for  comparison.}

\item{stateVariable}{Variable indicating patient disease states (e.g.,
stable, progressive,  deceased, remission). Should contain all possible
states that patients  can transition between during follow-up.}

\item{transitionTimeVariable}{Time variable indicating when state
transitions occurred. For multiple  transitions per patient, use
comma-separated times or separate records  for each transition.}

\item{multiStateStates}{Comma-separated list of all possible states in
order of progression  (e.g., "healthy, disease, death" or "stable,
progressive, remission, death").  Must match levels in the state variable.}

\item{absorptionStates}{Comma-separated list of absorbing states that
patients cannot leave  once entered (e.g., "death", "terminal"). These
represent final  outcomes in the disease process.}

\item{multiStateCovariates}{Additional variables to include in multi-state
models as covariates.  Include important prognostic factors that may
influence transition  rates between states.}

\item{calculateTransitionProbabilities}{Calculate state transition
probabilities between all possible state  pairs. Provides insight into
likelihood of disease progression,  remission, and mortality transitions.}

\item{multiStateTimePoints}{Time points for transition probability
calculations (e.g.,  "6, 12, 24, 36, 60" for 6-month intervals up to 5
years). Use  clinically relevant time points for disease monitoring.}

\item{generateTransitionMatrix}{Generate comprehensive transition intensity
matrix showing hazard  rates for all possible state transitions. Essential
for understanding  disease progression dynamics.}

\item{multiStateGraphics}{Generate multi-state model visualizations
including state transition  diagrams, probability plots, and Aalen-Johansen
estimator curves for  state occupancy probabilities.}

\item{msStratifyByStaging}{Perform separate multi-state analysis for each
staging system to  compare their ability to predict disease transitions and
progression  patterns.}

\item{multiStateValidation}{Perform model validation including
goodness-of-fit testing, residual  analysis, and cross-validation for
multi-state models. Computationally  intensive but provides robust model
assessment.}

\item{generateMSMSummary}{Generate comprehensive summary table with
transition intensities,  hazard ratios, and state occupancy probabilities
comparing staging  systems in multi-state framework.}

\item{performRandomForestAnalysis}{Perform Random Survival Forest analysis
as a non-parametric alternative  to Cox proportional hazards models.
Provides robust predictions through  ensemble methods without proportional
hazards assumptions, ideal for  complex interactions and non-linear
relationships.}

\item{forestModelType}{Type of random forest model to fit. RSF is the
standard approach,  conditional inference forests handle categorical
variables better,  extra trees provide additional randomization. Ensemble
combines  multiple approaches for maximum robustness.}

\item{forestNTrees}{Number of trees in the random forest. More trees
generally improve  performance but increase computation time. 500 trees
provide good  balance between accuracy and speed for most applications.}

\item{forestMTry}{Number of variables randomly selected at each split. Use
"auto" for  automatic selection (sqrt of total variables), or specify a
number.  Lower values increase randomization, higher values may improve
accuracy.}

\item{forestMinNodeSize}{Minimum number of observations in terminal nodes.
Larger values prevent  overfitting but may reduce model flexibility.
Recommended: 3-10 for  survival data depending on sample size.}

\item{forestCovariates}{Additional variables to include in random forest
models alongside  staging variables. Include important clinical variables
for  comprehensive non-parametric survival modeling.}

\item{calculateVariableImportance}{Calculate variable importance measures
using permutation-based methods.  Shows which variables contribute most to
survival predictions,  complementing SHAP analysis with forest-specific
importance metrics.}

\item{forestImportanceType}{Type of variable importance measure.
Permutation importance is most  interpretable, VIMP is RF-specific, minimal
depth shows variable  selection frequency. Comprehensive provides all
measures.}

\item{performForestValidation}{Perform out-of-bag validation and
cross-validation for random forest  models. Provides robust assessment of
model performance including  prediction error rates and concordance
indices.}

\item{forestPredictionTimePoints}{Time points for survival probability
predictions from random forest  models (e.g., "12, 24, 36, 60" for 1, 2, 3,
and 5-year predictions).  Use clinically relevant time points for staging
comparison.}

\item{generateSurvivalPredictions}{Generate individual patient survival
probability predictions at  specified time points. Provides personalized
risk assessments  based on random forest ensemble predictions.}

\item{forestDiscriminationMetrics}{Calculate discrimination metrics
specifically for random forest models  including C-index, Integrated Brier
Score, and time-dependent AUC.  Compares forest performance with
traditional Cox models.}

\item{forestStagingComparison}{Use random forest models to compare staging
systems through  non-parametric ensemble methods. Provides robust staging
comparison  without proportional hazards assumptions.}

\item{forestBootstrap}{Perform bootstrap validation of random forest models
with multiple  bootstrap samples. Provides confidence intervals for
forest-based  predictions and importance measures.}

\item{forestBootstrapSamples}{Number of bootstrap samples for forest
validation. More samples  provide more stable confidence intervals but
increase computation time.}

\item{generateForestSummary}{Generate comprehensive summary of random
forest analysis including  model performance, variable importance, staging
comparison, and  clinical recommendations based on ensemble predictions.}

\item{performCureModelAnalysis}{Perform cure model analysis for populations
where a fraction of patients  may be effectively cured. Uses mixture models
to separate susceptible  and cured populations, particularly relevant for
cancer staging analysis.}

\item{cureModelType}{Type of cure model to fit. Mixture models assume a
cured fraction with  infinite survival, promotion time models use
biological mechanisms,  and both provides comprehensive comparison.}

\item{cureDistribution}{Underlying survival distribution for the
susceptible population in  cure models. Weibull is most flexible,
exponential is simplest,  log-normal and log-logistic provide alternative
hazard shapes.}

\item{cureAnalyzeOldStage}{Fit cure models to original staging system to
estimate cure fractions  and survival patterns for susceptible patients in
each stage.}

\item{cureAnalyzeNewStage}{Fit cure models to new staging system to
estimate cure fractions and  survival patterns, enabling comparison of
staging discrimination for  both cured and susceptible populations.}

\item{cureFractionEstimation}{Method for estimating cure fractions.
Parametric uses maximum likelihood  with specified distributions,
non-parametric uses Kaplan-Meier plateau  detection, both provides
validation.}

\item{cureConfidenceLevel}{Confidence level for cure model parameter
estimates and cure fraction  confidence intervals. Standard 95\\% provides
balance between precision  and coverage.}

\item{cureBootstrapCI}{Calculate bootstrap confidence intervals for cure
fractions and model  parameters. Provides robust uncertainty quantification
especially for  small samples or complex models.}

\item{cureBootstrapReps}{Number of bootstrap replications for confidence
interval calculation.  More replications provide more stable intervals but
increase  computation time.}

\item{cureTimeHorizon}{Time horizon for cure assessment in months. Patients
surviving beyond  this time without events are considered potentially
cured. Typical  values: 60-120 months for most cancers.}

\item{curePlateauThreshold}{Threshold for detecting survival curve plateau
in non-parametric cure  fraction estimation. Lower values detect smaller
plateaus but may be  more sensitive to noise.}

\item{cureCovariates}{Additional variables to include in cure model
analysis alongside staging  variables. Can affect both cure probability and
survival of susceptible  patients.}

\item{cureModelComparison}{Compare cure models between staging systems
using likelihood ratio tests,  AIC/BIC criteria, and cure fraction
differences. Assesses which staging  system better identifies cured
patients.}

\item{cureStageSpecificAnalysis}{Perform separate cure model analysis for
each stage group to understand  stage-specific cure patterns and survival
of susceptible patients.  Essential for staging validation.}

\item{cureGoodnessOfFit}{Perform goodness-of-fit tests for cure models
including Kolmogorov-Smirnov  tests and visual diagnostic plots. Validates
model assumptions and  identifies potential misspecification.}

\item{generateCureSummary}{Generate comprehensive summary of cure model
analysis including cure  fractions by stage, model comparison results, and
clinical interpretation  for staging system evaluation.}

\item{performIntervalCensoringAnalysis}{Perform interval censoring analysis
for events detected between visits. This handles cases where the exact
event time is unknown but falls  within a known interval (e.g., between
clinic visits). Uses icenReg  package for non-parametric and parametric
interval-censored survival  analysis.}

\item{intervalCensoringLeftTime}{Variable containing the left endpoint of
the censoring interval. For exact observations, this should equal the right
endpoint. For left-censored observations, use 0 or NA.}

\item{intervalCensoringRightTime}{Variable containing the right endpoint of
the censoring interval. For right-censored observations, use Inf or a large
value. For exact observations, this should equal the left endpoint.}

\item{intervalCensoringDistribution}{Distribution assumption for parametric
interval-censored regression. Weibull is most commonly used and provides
good flexibility.}

\item{intervalCensoringModel}{Type of interval censoring model to fit.
Non-parametric uses non-parametric maximum likelihood estimation (NPMLE).
Parametric fits accelerated failure time models with specified
distribution.}

\item{intervalCensoringBootstrap}{Calculate bootstrap confidence intervals
for non-parametric estimates. This provides uncertainty quantification for
the survival function estimates with interval-censored data.}

\item{intervalCensoringBootstrapSamples}{Number of bootstrap samples for
confidence interval calculation. More samples provide more accurate
intervals but increase computation time.}

\item{intervalCensoringCompareStages}{Compare survival functions between
different staging systems accounting for interval censoring. Provides
likelihood ratio tests and information criteria for model comparison.}

\item{intervalCensoringPlots}{Generate survival plots specifically designed
for interval-censored data, including non-parametric survival function
estimates and comparison plots between staging systems.}

\item{intervalCensoringDiagnostics}{Perform model diagnostics including
convergence assessment, residual analysis for parametric models, and
goodness-of-fit tests for interval-censored regression models.}

\item{intervalCensoringPredictionTime}{Comma-separated list of time points
(in months) for survival probability predictions. These will be used for
staging system comparison and clinical interpretation of interval-censored
survival estimates.}

\item{intervalCensoringConfidenceLevel}{Confidence level for interval
estimates and hypothesis tests. Standard choices are 0.90, 0.95, or 0.99.}

\item{intervalCensoringAdjustVariables}{Additional variables to include in
parametric interval-censored regression models for adjusted survival
analysis. These will be included as covariates in the accelerated failure
time model.}

\item{performInformativeCensoringAnalysis}{Perform tests for informative
censoring to validate the assumption that censoring is non-informative.
Informative censoring occurs when the censoring mechanism is related to the
failure time, potentially biasing survival estimates. This analysis
provides tests and adjustments for non-random censoring patterns.}

\item{informativeCensoringTestMethod}{Method for testing informative
censoring. Correlation tests examine relationship between censoring and
survival times. Regression tests model censoring as outcome. Competing
risks treats censoring as competing event. Landmark analysis examines
censoring patterns.}

\item{informativeCensoringCovariates}{Variables that may be associated with
the censoring mechanism. These could include clinical factors, treatment
decisions, or administrative factors that might influence when patients are
censored from the study.}

\item{informativeCensoringLandmarkTimes}{Comma-separated list of landmark
time points (in months) for landmark analysis of censoring patterns.
Analysis examines whether censoring probabilities differ across staging
groups at these specific time points.}

\item{informativeCensoringAdjustmentMethod}{Method for adjusting survival
estimates when informative censoring is detected. IPW uses inverse
probability weighting. Multiple imputation imputes censored failure times.
Sensitivity analysis explores range of possible bias effects.}

\item{informativeCensoringIPWVariables}{Variables to include in inverse
probability weighting model for censoring probability estimation. Should
include factors that predict censoring but are not affected by the outcome.}

\item{informativeCensoringSensitivityRange}{Comma-separated list of
sensitivity parameters for bias analysis. These represent hazard ratio
multipliers for exploring potential bias from informative censoring (1.0 =
no bias assumption).}

\item{informativeCensoringBootstrap}{Calculate bootstrap confidence
intervals for adjusted survival estimates and bias-corrected parameters.
Provides uncertainty quantification for informative censoring adjustments.}

\item{informativeCensoringBootstrapSamples}{Number of bootstrap samples for
confidence interval calculation in informative censoring analysis. More
samples provide more accurate intervals but increase computation time.}

\item{informativeCensoringAlpha}{Significance level for testing informative
censoring hypotheses. Used for determining whether censoring appears to be
informative and for confidence interval construction.}

\item{informativeCensoringPlots}{Generate diagnostic plots for informative
censoring assessment including censoring probability over time, correlation
plots, and sensitivity analysis visualizations.}

\item{informativeCensoringCompareStages}{Compare censoring patterns across
different staging groups to assess whether censoring differs by stage,
which could indicate stage-related informative censoring that affects
staging system evaluation.}

\item{performConcordanceProbabilityAnalysis}{Perform advanced concordance
probability analysis for heavily censored data. This provides alternative
concordance measures beyond traditional C-index, including Harrell's
C-index modifications, Uno's C-index for heavily censored data, and
time-dependent concordance measures specifically designed for staging
system evaluation with high censoring rates.}

\item{concordanceProbabilityMethods}{Concordance probability estimation
methods. Harrell C-index is traditional but may be biased with heavy
censoring. Uno C-index uses inverse probability weighting for censoring.
Time-dependent measures evaluate concordance at specific time points. IPCW
and weighted methods provide robust alternatives.}

\item{concordanceProbabilityTimePoints}{Comma-separated list of time points
(in months) for time-dependent concordance assessment. These will be used
for evaluating staging system discrimination at clinically relevant time
horizons.}

\item{concordanceProbabilityWeighting}{Weighting strategy for concordance
probability estimation. Uniform gives equal weight to all pairs. Sample
size weights by stage frequency. Event rate weights by observed events.
Follow-up weights by observation time. Inverse variance uses precision
weighting.}

\item{concordanceProbabilityBootstrap}{Calculate bootstrap confidence
intervals for concordance probability estimates. This provides uncertainty
quantification for discrimination measures, especially important for
heavily censored data where traditional standard errors may be unreliable.}

\item{concordanceProbabilityBootstrapSamples}{Number of bootstrap samples
for confidence interval calculation. More samples provide more accurate
intervals but increase computation time. Recommended minimum 500 for
reliable confidence intervals.}

\item{concordanceProbabilityConfidenceLevel}{Confidence level for
concordance probability confidence intervals. Standard choices are 0.90,
0.95, or 0.99 for 90\\%, 95\\%, or 99\\% confidence intervals respectively.}

\item{concordanceProbabilityCompareStages}{Compare concordance
probabilities between different staging systems using hypothesis tests and
confidence interval overlap assessment. Provides statistical evidence for
staging system discrimination differences accounting for heavy censoring.}

\item{concordanceProbabilityAdjustVariables}{Additional variables to
include in adjusted concordance analysis. These variables will be included
alongside staging in multivariable models to assess staging contribution to
discrimination beyond other prognostic factors.}

\item{concordanceProbabilityRobustnessAnalysis}{Perform robustness analysis
for concordance probability estimates including sensitivity to censoring
assumptions, outlier influence, and temporal stability assessment for
comprehensive validation of staging system discrimination.}

\item{concordanceProbabilityAlpha}{Significance level for concordance
probability hypothesis tests and confidence interval construction. Used for
testing differences between staging systems and assessing statistical
significance of discrimination improvements.}

\item{concordanceProbabilityDiagnostics}{Perform diagnostic assessment of
concordance probability estimates including convergence checks, influence
diagnostics, and sensitivity analysis to ensure reliable discrimination
assessment for staging system evaluation.}

\item{performWinRatioAnalysis}{Perform win ratio analysis for composite
endpoint analysis in staging comparison. The win ratio is a novel method
for analyzing composite endpoints that respects the clinical hierarchy of
outcomes and provides intuitive interpretation for staging system
evaluation.}

\item{winRatioEndpoints}{Clinical hierarchy of endpoints for win ratio
analysis. More important outcomes are prioritized in the analysis. Death is
typically the most important endpoint, followed by disease-specific
outcomes. The hierarchy determines how patient pairs are compared.}

\item{winRatioDeathVariable}{Variable indicating death or primary endpoint
occurrence (1 = event, 0 = no event). This is typically the most important
outcome in the hierarchy and is compared first when evaluating patient
pairs.}

\item{winRatioSecondaryEndpoint}{Variable for secondary endpoint (e.g.,
disease progression, recurrence). This endpoint is evaluated when the
primary endpoint comparison is tied. Can be binary (event/no event) or
continuous (time to event).}

\item{winRatioTertiaryEndpoint}{Variable for tertiary endpoint (e.g.,
response, quality of life). This endpoint is evaluated when both primary
and secondary comparisons are tied. Can be binary or continuous.}

\item{winRatioTimeVariables}{Time variables corresponding to each endpoint
in the hierarchy. Should be provided in the same order as the endpoints.
Used for time-to-event comparisons when endpoints are not binary.}

\item{winRatioMatchingStrategy}{Strategy for forming patient pairs for
comparison. All pairs compares every patient from one group with every
patient from another. Matched pairs uses pre-specified matching. Stratified
performs within-stage comparisons. Propensity matching balances baseline
characteristics.}

\item{winRatioConfidenceMethod}{Method for calculating confidence intervals
for the win ratio. Bootstrap is most robust but computationally intensive.
Asymptotic uses large sample theory. Permutation provides exact p-values.}

\item{winRatioBootstrapSamples}{Number of bootstrap samples for confidence
interval calculation when using bootstrap method. More samples provide more
accurate intervals but increase computation time.}

\item{winRatioConfidenceLevel}{Confidence level for win ratio confidence
intervals and hypothesis tests. Standard choices are 0.90, 0.95, or 0.99
for 90\\%, 95\\%, or 99\\% confidence intervals respectively.}

\item{winRatioHandleTies}{Strategy for handling tied comparisons. Split
assigns 0.5 wins to each. Ignore excludes tied pairs from analysis. Next
endpoint proceeds to compare the next outcome in the hierarchy for tied
pairs.}

\item{winRatioSensitivityAnalysis}{Perform sensitivity analysis for win
ratio including assessment of endpoint ordering impact, missing data
influence, and robustness to matching strategy choices.}

\item{winRatioGeneralizedPairwise}{Use generalized pairwise comparison
(GPC) framework which extends win ratio to include continuous outcomes and
provides additional metrics like net benefit and win odds.}

\item{performFrailtyModelsAnalysis}{Perform frailty models analysis for
clustered survival data using  mixed-effects Cox models (coxme) for
multi-institutional data with  center-specific random effects and
clustering adjustments.}

\item{frailtyClusterVariable}{Variable defining clusters/institutions for
frailty modeling (e.g.,  hospital, center, surgeon). Used to account for
unobserved  heterogeneity and clustering effects in survival analysis.}

\item{frailtyDistribution}{Distribution assumption for the frailty (random
effects) terms. Gamma distribution is most common and provides
multiplicative  frailty effects on the hazard function.}

\item{frailtyBootstrap}{Perform bootstrap validation for frailty model
parameters and  variance components to assess model stability and provide
robust confidence intervals.}

\item{frailtyBootstrapSamples}{Number of bootstrap samples for frailty
model validation.  Higher values provide more stable estimates but increase
computational time.}

\item{frailtyVarianceComponents}{Analyze variance components to quantify
the proportion of  total variation explained by cluster-level random
effects  vs individual-level factors.}

\item{frailtyHeterogeneityTest}{Test for significant frailty/heterogeneity
using likelihood  ratio tests comparing frailty models to standard Cox
models  without random effects.}

\item{frailtyClusterComparison}{Perform cluster-specific survival analysis
comparing staging  systems within each cluster/institution to assess
consistency  of staging performance across centers.}

\item{frailtyModelSelection}{Perform systematic model selection comparing
different frailty  distributions and model specifications using AIC/BIC
criteria  and likelihood ratio tests.}

\item{frailtyPredictiveAccuracy}{Assess predictive accuracy of frailty
models using cross-validation  and concordance measures accounting for
clustering structure in  the data.}

\item{frailtyDiagnostics}{Comprehensive model diagnostics including
residual analysis,  influence detection, and goodness-of-fit assessment for
frailty  models with clustering adjustments.}

\item{frailtyAdvancedInference}{Advanced statistical inference including
profile likelihood  confidence intervals, score tests, and robust variance
estimation for complex frailty model specifications.}

\item{performClinicalUtilityAnalysis}{Perform clinical utility index
analysis combining sensitivity/specificity  with disease prevalence to
assess clinical decision-making value of  staging systems beyond
statistical discrimination.}

\item{clinicalUtilityPrevalence}{Disease prevalence (proportion with
events) for clinical utility  calculations. Can be estimated from study
data or specified based  on population characteristics.}

\item{clinicalUtilityTimePoint}{Time point (in months) for clinical utility
assessment. Should  represent clinically relevant decision-making horizon
for the  specific cancer type and staging system.}

\item{clinicalUtilityThresholds}{Range of risk thresholds for clinical
utility assessment. Different  ranges appropriate for different clinical
decision contexts and  treatment aggressiveness preferences.}

\item{clinicalUtilityNNT}{Calculate Number Needed to Treat (NNT) and Number
Needed to Harm (NNH)  based on staging-guided interventions with
configurable treatment  effect assumptions.}

\item{clinicalUtilityTreatmentEffect}{Assumed treatment effect (hazard
ratio) for calculating NNT/NNH.  Should reflect realistic treatment
benefits for staging-guided  interventions in the specific clinical
context.}

\item{clinicalUtilityComparison}{Compare clinical utility between staging
systems using net benefit  difference analysis and utility improvement
quantification across  different risk thresholds.}

\item{clinicalUtilityCostEffectiveness}{Include basic cost-effectiveness
considerations in clinical utility  assessment with configurable cost
assumptions for staging-guided  interventions and outcomes.}

\item{clinicalUtilityCostPerIntervention}{Estimated cost per staging-guided
intervention for cost-effectiveness  analysis. Should reflect realistic
healthcare costs in the relevant  healthcare system and setting.}

\item{clinicalUtilityBootstrap}{Perform bootstrap validation for clinical
utility metrics including  confidence intervals for NNT, net benefit
differences, and utility  improvement measures.}

\item{clinicalUtilityBootstrapSamples}{Number of bootstrap samples for
clinical utility validation. Higher  values provide more stable estimates
but increase computational time.}

\item{clinicalUtilityTimeVarying}{Assess clinical utility across multiple
time points to understand  how staging system value changes over time
horizon and identify  optimal decision timing.}
}
\value{
A results object containing:
\tabular{llllll}{
\code{results$welcomeMessage} \tab \tab \tab \tab \tab a html \cr
\code{results$copyReadyReport} \tab \tab \tab \tab \tab a html \cr
\code{results$guidedModeProgress} \tab \tab \tab \tab \tab a html \cr
\code{results$mydataview} \tab \tab \tab \tab \tab a preformatted \cr
\code{results$mydataview2} \tab \tab \tab \tab \tab a preformatted \cr
\code{results$migrationOverviewExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$migrationOverview} \tab \tab \tab \tab \tab a table \cr
\code{results$migrationMatrixExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$migrationMatrix} \tab \tab \tab \tab \tab a table \cr
\code{results$stageDistributionExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$stageDistribution} \tab \tab \tab \tab \tab a table \cr
\code{results$migrationSummaryExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$migrationSummary} \tab \tab \tab \tab \tab a table \cr
\code{results$statisticalComparisonExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$statisticalComparison} \tab \tab \tab \tab \tab a table \cr
\code{results$concordanceComparisonExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$concordanceComparison} \tab \tab \tab \tab \tab a table \cr
\code{results$nriResultsExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$nriResults} \tab \tab \tab \tab \tab a table \cr
\code{results$idiResultsExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$idiResults} \tab \tab \tab \tab \tab a table \cr
\code{results$multifactorialAnalysisExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$multifactorialResults} \tab \tab \tab \tab \tab a table \cr
\code{results$multifactorialResultsExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$adjustedCIndexComparison} \tab \tab \tab \tab \tab a table \cr
\code{results$adjustedCIndexComparisonExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$nestedModelTests} \tab \tab \tab \tab \tab a table \cr
\code{results$nestedModelTestsExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$stepwiseResults} \tab \tab \tab \tab \tab a table \cr
\code{results$stepwiseResultsExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$interactionTests} \tab \tab \tab \tab \tab a table \cr
\code{results$interactionTestsExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$stratifiedAnalysis} \tab \tab \tab \tab \tab a table \cr
\code{results$stratifiedAnalysisExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$rocAnalysis} \tab \tab \tab \tab \tab a table \cr
\code{results$integratedAUCAnalysis} \tab \tab \tab \tab \tab a table \cr
\code{results$dcaResultsExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$dcaResults} \tab \tab \tab \tab \tab a table \cr
\code{results$pseudoR2ResultsExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$pseudoR2Results} \tab \tab \tab \tab \tab a table \cr
\code{results$decisionCurvesExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$decisionCurves} \tab \tab \tab \tab \tab an image \cr
\code{results$bootstrapResults} \tab \tab \tab \tab \tab a table \cr
\code{results$bootstrapValidationExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$willRogersAnalysisExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$willRogersBasicAnalysis} \tab \tab \tab \tab \tab a table \cr
\code{results$likelihoodTestsExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$likelihoodTests} \tab \tab \tab \tab \tab a table \cr
\code{results$linearTrendTestExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$linearTrendTest} \tab \tab \tab \tab \tab a table \cr
\code{results$homogeneityTestsExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$homogeneityTests} \tab \tab \tab \tab \tab a table \cr
\code{results$trendTestsExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$trendTests} \tab \tab \tab \tab \tab a table \cr
\code{results$clinicalInterpretationExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$clinicalInterpretation} \tab \tab \tab \tab \tab a table \cr
\code{results$executiveSummaryExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$executiveSummary} \tab \tab \tab \tab \tab a table \cr
\code{results$statisticalSummaryExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$statisticalSummary} \tab \tab \tab \tab \tab a table \cr
\code{results$effectSizesExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$effectSizes} \tab \tab \tab \tab \tab a table \cr
\code{results$methodologyNotes} \tab \tab \tab \tab \tab a html \cr
\code{results$migrationHeatmapExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$migrationHeatmap} \tab \tab \tab \tab \tab an image \cr
\code{results$sankeyDiagram} \tab \tab \tab \tab \tab an image \cr
\code{results$rocComparisonExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$rocComparisonPlot} \tab \tab \tab \tab \tab an image \cr
\code{results$forestPlotExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$forestPlot} \tab \tab \tab \tab \tab an image \cr
\code{results$calibrationAnalysisExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$calibrationAnalysis} \tab \tab \tab \tab \tab a table \cr
\code{results$calibrationPlotsExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$calibrationPlots} \tab \tab \tab \tab \tab an image \cr
\code{results$advancedMigrationExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$monotonicityCheck} \tab \tab \tab \tab \tab a table \cr
\code{results$willRogersAnalysis} \tab \tab \tab \tab \tab a table \cr
\code{results$willRogersVisualization} \tab \tab \tab \tab \tab an image \cr
\code{results$migrationSurvivalComparison} \tab \tab \tab \tab \tab an image \cr
\code{results$willRogersEnhancedAnalysis} \tab \tab \tab \tab \tab a table \cr
\code{results$willRogersStageDetail} \tab \tab \tab \tab \tab a table \cr
\code{results$stageSpecificCIndex} \tab \tab \tab \tab \tab a table \cr
\code{results$enhancedPseudoR2} \tab \tab \tab \tab \tab a table \cr
\code{results$enhancedReclassificationMetrics} \tab \tab \tab \tab \tab a table \cr
\code{results$proportionalHazardsTest} \tab \tab \tab \tab \tab a table \cr
\code{results$decisionCurveAnalysis} \tab \tab \tab \tab \tab a table \cr
\code{results$survivalCurvesExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$survivalCurves} \tab \tab \tab \tab \tab an image \cr
\code{results$dashboardExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$comparativeAnalysisDashboard} \tab \tab \tab \tab \tab a table \cr
\code{results$willRogersEvidenceSummaryExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$willRogersEvidenceSummary} \tab \tab \tab \tab \tab a table \cr
\code{results$willRogersClinicalRecommendation} \tab \tab \tab \tab \tab a table \cr
\code{results$enhancedMigrationPatternAnalysis} \tab \tab \tab \tab \tab a table \cr
\code{results$landmarkAnalysisResults} \tab \tab \tab \tab \tab a table \cr
\code{results$advancedMigrationHeatmapStats} \tab \tab \tab \tab \tab a table \cr
\code{results$abbreviationGlossary} \tab \tab \tab \tab \tab a html \cr
\code{results$crossValidationExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$crossValidationResults} \tab \tab \tab \tab \tab a table \cr
\code{results$crossValidationPlot} \tab \tab \tab \tab \tab an image \cr
\code{results$enhancedLRComparison} \tab \tab \tab \tab \tab a table \cr
\code{results$stageMigrationEffectExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$stageMigrationEffect} \tab \tab \tab \tab \tab a table \cr
\code{results$stageMigrationEffectAssessment} \tab \tab \tab \tab \tab a table \cr
\code{results$rmstAnalysisExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$rmstByStage} \tab \tab \tab \tab \tab a table \cr
\code{results$rmstComparison} \tab \tab \tab \tab \tab a table \cr
\code{results$competingRisksExplanation} \tab \tab \tab \tab \tab a html \cr
\code{results$competingRisksEventDistribution} \tab \tab \tab \tab \tab a table \cr
\code{results$competingRisksComparison} \tab \tab \tab \tab \tab a table \cr
\code{results$optimalCutpointAnalysis} \tab \tab \tab \tab \tab a table \cr
\code{results$cutpointValidation} \tab \tab \tab \tab \tab a table \cr
\code{results$generatedStagingSystem} \tab \tab \tab \tab \tab a table \cr
\code{results$shapGlobalImportance} \tab \tab \tab \tab \tab a table \cr
\code{results$shapIndividualExplanations} \tab \tab \tab \tab \tab a table \cr
\code{results$shapInteractions} \tab \tab \tab \tab \tab a table \cr
\code{results$shapSummaryStats} \tab \tab \tab \tab \tab a table \cr
\code{results$fineGrayResults} \tab \tab \tab \tab \tab a table \cr
\code{results$causeSpecificResults} \tab \tab \tab \tab \tab a table \cr
\code{results$cifSummary} \tab \tab \tab \tab \tab a table \cr
\code{results$competingRisksCIndex} \tab \tab \tab \tab \tab a table \cr
\code{results$competingRisksSummary} \tab \tab \tab \tab \tab a table \cr
\code{results$transitionIntensities} \tab \tab \tab \tab \tab a table \cr
\code{results$transitionProbabilities} \tab \tab \tab \tab \tab a table \cr
\code{results$stateOccupancy} \tab \tab \tab \tab \tab a table \cr
\code{results$multiStateComparison} \tab \tab \tab \tab \tab a table \cr
\code{results$multiStateSummary} \tab \tab \tab \tab \tab a table \cr
\code{results$forestVariableImportance} \tab \tab \tab \tab \tab a table \cr
\code{results$forestModelPerformance} \tab \tab \tab \tab \tab a table \cr
\code{results$forestSurvivalPredictions} \tab \tab \tab \tab \tab a table \cr
\code{results$forestCoxComparison} \tab \tab \tab \tab \tab a table \cr
\code{results$forestStagingComparison} \tab \tab \tab \tab \tab a table \cr
\code{results$forestAnalysisSummary} \tab \tab \tab \tab \tab a table \cr
\code{results$cureFractionEstimates} \tab \tab \tab \tab \tab a table \cr
\code{results$cureModelParameters} \tab \tab \tab \tab \tab a table \cr
\code{results$cureModelComparison} \tab \tab \tab \tab \tab a table \cr
\code{results$stageSpecificCureAnalysis} \tab \tab \tab \tab \tab a table \cr
\code{results$cureModelBootstrap} \tab \tab \tab \tab \tab a table \cr
\code{results$cureAnalysisSummary} \tab \tab \tab \tab \tab a table \cr
\code{results$intervalCensoringOverview} \tab \tab \tab \tab \tab Summary of interval-censored data characteristics and model selection \cr
\code{results$intervalCensoringNonparametric} \tab \tab \tab \tab \tab Non-parametric maximum likelihood survival estimates for interval-censored data \cr
\code{results$intervalCensoringParametric} \tab \tab \tab \tab \tab Parametric survival regression results for interval-censored data \cr
\code{results$intervalCensoringComparison} \tab \tab \tab \tab \tab Model comparison between staging systems accounting for interval censoring \cr
\code{results$intervalCensoringDiagnosticsTable} \tab \tab \tab \tab \tab Diagnostic measures for interval-censored survival models \cr
\code{results$intervalCensoringSummary} \tab \tab \tab \tab \tab Clinical interpretation and recommendations for interval-censored survival analysis \cr
\code{results$informativeCensoringOverview} \tab \tab \tab \tab \tab Summary of informative censoring detection analysis and data characteristics \cr
\code{results$informativeCensoringTests} \tab \tab \tab \tab \tab Statistical tests for detecting informative censoring patterns \cr
\code{results$informativeCensoringByStage} \tab \tab \tab \tab \tab Comparison of censoring patterns across staging groups \cr
\code{results$informativeCensoringAdjustment} \tab \tab \tab \tab \tab Survival estimates adjusted for informative censoring effects \cr
\code{results$informativeCensoringSensitivity} \tab \tab \tab \tab \tab Sensitivity analysis exploring range of potential bias from informative censoring \cr
\code{results$informativeCensoringDiagnostics} \tab \tab \tab \tab \tab Diagnostic measures for informative censoring assessment \cr
\code{results$informativeCensoringSummary} \tab \tab \tab \tab \tab Summary of informative censoring findings and recommendations \cr
\code{results$concordanceProbabilityOverview} \tab \tab \tab \tab \tab Summary of concordance probability analysis for staging system discrimination assessment \cr
\code{results$concordanceProbabilityEstimates} \tab \tab \tab \tab \tab Concordance probability estimates using multiple methods for robust discrimination assessment \cr
\code{results$concordanceProbabilityTimeDependentComplex} \tab \tab \tab \tab \tab Time-dependent concordance probability estimates at clinically relevant time points \cr
\code{results$concordanceProbabilityComparison} \tab \tab \tab \tab \tab Statistical comparison of concordance probabilities between staging systems \cr
\code{results$concordanceProbabilityRobustness} \tab \tab \tab \tab \tab Robustness analysis for concordance probability estimates under different assumptions \cr
\code{results$concordanceProbabilityDiagnosticsTable} \tab \tab \tab \tab \tab Diagnostic measures for concordance probability analysis validation \cr
\code{results$concordanceProbabilitySummary} \tab \tab \tab \tab \tab Summary of concordance probability findings and clinical interpretation \cr
\code{results$winRatioOverview} \tab \tab \tab \tab \tab Summary of win ratio analysis configuration and data characteristics \cr
\code{results$winRatioPrimaryResults} \tab \tab \tab \tab \tab Primary win ratio analysis results comparing staging systems \cr
\code{results$winRatioEndpointContributions} \tab \tab \tab \tab \tab Contribution of each endpoint to the overall win ratio \cr
\code{results$winRatioStageSpecific} \tab \tab \tab \tab \tab Win ratio analysis stratified by staging categories \cr
\code{results$winRatioSensitivityResults} \tab \tab \tab \tab \tab Sensitivity analysis results for win ratio estimates \cr
\code{results$winRatioGeneralizedPairwiseResults} \tab \tab \tab \tab \tab Extended metrics from generalized pairwise comparison framework \cr
\code{results$winRatioSummary} \tab \tab \tab \tab \tab Summary of win ratio findings and clinical interpretation \cr
\code{results$frailtyModelsOverview} \tab \tab \tab \tab \tab Overview of frailty models analysis for clustered survival data \cr
\code{results$frailtyModelsComparison} \tab \tab \tab \tab \tab Comparison of staging systems using frailty models with clustering adjustments \cr
\code{results$frailtyModelsVarianceComponents} \tab \tab \tab \tab \tab Detailed variance components analysis for frailty models \cr
\code{results$frailtyModelsClusterSpecific} \tab \tab \tab \tab \tab Cluster-specific survival analysis comparing staging systems within institutions \cr
\code{results$frailtyModelsBootstrap} \tab \tab \tab \tab \tab Bootstrap validation results for frailty model parameters and variance components \cr
\code{results$frailtyModelsDiagnostics} \tab \tab \tab \tab \tab Comprehensive model diagnostics for frailty models including residual analysis and goodness-of-fit \cr
\code{results$frailtyModelsSummary} \tab \tab \tab \tab \tab Executive summary of frailty models analysis with evidence-based recommendations \cr
\code{results$clinicalUtilityOverview} \tab \tab \tab \tab \tab Overview of clinical utility index analysis combining discrimination with clinical decision-making value \cr
\code{results$clinicalUtilityComparison} \tab \tab \tab \tab \tab Comparison of clinical utility between staging systems across different risk thresholds \cr
\code{results$clinicalUtilityNNT} \tab \tab \tab \tab \tab Number Needed to Treat (NNT) and Number Needed to Harm (NNH) analysis for staging-guided interventions \cr
\code{results$clinicalUtilityNetBenefit} \tab \tab \tab \tab \tab Net benefit analysis across risk thresholds with comparative utility assessment \cr
\code{results$clinicalUtilityTimeVarying} \tab \tab \tab \tab \tab Time-varying clinical utility analysis showing how staging system value changes over time \cr
\code{results$clinicalUtilityBootstrap} \tab \tab \tab \tab \tab Bootstrap validation results for clinical utility metrics with confidence intervals \cr
\code{results$clinicalUtilitySummary} \tab \tab \tab \tab \tab Executive summary of clinical utility analysis with evidence-based recommendations \cr
}

Tables can be converted to data frames with \code{asDF} or \code{\link{as.data.frame}}. For example:

\code{results$migrationOverview$asDF}

\code{as.data.frame(results$migrationOverview)}
}
\description{
Comprehensive analysis for validating TNM staging system improvements using
state-of-the-art  statistical methods. This analysis provides pathologists
with robust tools to evaluate whether  a new staging system provides
superior prognostic discrimination compared to existing systems.
Includes advanced metrics: Net Reclassification Improvement (NRI),
Integrated Discrimination  Improvement (IDI), time-dependent ROC analysis,
decision curve analysis, bootstrap validation,  and comprehensive clinical
interpretation guidance.
}
\examples{
\donttest{
# Example analyzing TNM staging system migration:
# stagemigration(
#   data = cancer_cohort,
#   oldStage = "tnm7_stage",
#   newStage = "tnm8_stage",
#   survivalTime = "os_months",
#   event = "death_status",
#   eventLevel = "Dead",
#   analysisType = "comprehensive",
#   calculateNRI = TRUE,
#   calculateIDI = TRUE,
#   performBootstrap = TRUE,
#   bootstrapReps = 1000
# )
}
}
